Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Second phase I study of huN901-DM1 under way

Aug. 13, 2002

Cancer targets selected from Exelixis and Bristol-Myers Squibb collaboration

Aug. 13, 2002

First in vitro study of P80DOX-NP completed

Aug. 12, 2002

Targeted Genetics restructures

Aug. 12, 2002

Biomed-101 phase Ib enrollment completed

Aug. 12, 2002

Initial phase I results for Large Scale Biology's personalized NHL vaccines

Aug. 12, 2002

ProlX receives SBIR grant to advance HIF inhibitor cancer therapy

Aug. 12, 2002

The CXCR4-CXCL12/SDF-1 pathway is a possible target for non-Hodgkin's lymphoma therapy

Aug. 12, 2002

Novel HDAC inhibitors identified at Beacon

Aug. 9, 2002

Pivotal phase III trial of RSR-13 completes enrollment

Aug. 9, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...